Stock Detail
VERTEX PHARMACEUTICALS INCORPORATED
Biotechnology
VRTX @ Yahoo Finance | VRTX Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $29.26 | $30.00 | $-0.44 | -1.48% | 0.00 | $29.70 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $29.61 | $29.18 | 3.24M | 6.1B | 3.26M | -19.12 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 30.30 | 29.78 | 29.48 | 28.96 | 28.66 |
Stock Profile
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in the discovery, development, and commercialization of small molecule drugs for HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, pain, and bacterial infection. It offers Lexiva/Telzir and Agenerase for HIV infection. The company is developing Merimepodib and VX-950, which are in phase I and phase II stage; VX-765, VX-702, and Pralnacasan that are in phase II stage; VX-680, VX-944, and VX-322, which are in phase I and preclinical stage; and VX-409 and VX-692, that are in preclinical stage. Vertex Pharmaceuticals has collaboration agreements with Aventis S.A.; GlaxoSmithKline plc; Novartis Pharma AG; Merck & Co., Inc.; Mitsubishi Pharma Corp.; and Cystic Fibrosis Foundation Therapeutics Incorporated. It also has collaboration agreements with Schering AG; Kissei Pharmaceutical Co., Ltd.; and Eli Lilly and Company. In addition, it has a licensing agreement with Avalon Pharmaceuticals, Inc. for the development and commercialization of the IMPDH inhibitor VX-944 for the treatment of cancer. Vertex Pharmaceuticals was founded by Joshua Boger in 1989 and is headquartered in Cambridge, Massachusetts.